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Abstract
The ease of direct-acting antiviral (DAA) medications for hepatitis C virus (HCV) 
has provided an opportunity to decentralize HCV treatment into community set-
tings. However, the role of non-specialist clinicians in community-based pathways 
has received scant attention to date. This study examined barriers and enablers to 
expanding the role of general practitioners (GPs) in HCV treatment provision, using 
simple behaviour change theory as a conceptual framework. A maximum variation 
sample of 22 HCV treatment providers, GPs and HCV support workers participated 
in semi-structured interviews. Data were inductively coded, and the resulting codes 
deductively mapped into three principal components of behaviour change: capabil-
ity, opportunity and motivation (COM-B). By this process, a number of provider- and 
systemic-level barriers and enablers were identified. Key barriers included the pre-
treatment assessment of liver fibrosis, GP capacity and the ‘speciality’ of HCV care. 
Enablers included the simplicity of the drugs, existing GP/patient relationships and 
the provision of holistic care. In addition to these specific factors, the data also ex-
posed an overarching provider understanding of ‘HCV treatment’ as triumvirate in 
nature, incorporating the assessment of liver fibrosis, the provision of holistic support 
and the treatment of disease. This understanding imposes a further fundamental bar-
rier to GP-led treatment as each of these three components needs to be individually 
addressed. To enable sustainable models of HCV treatment provision by GPs, a prag-
matic re-examination of the ‘HCV treatment triumvirate’ is required, and a paradigm 
shift from the ‘refer and treat’ status quo.
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1  |  INTRODUC TION
Scotland's hepatitis C virus (HCV) strategy aims to achieve elimination 
of the virus as a major public health concern by 2024 at the latest.1 To 
enable this, health boards have been encouraged to expand their mod-
els of care beyond traditional, specialist-led hospital settings and into 
the community, adopting more eclectic patient pathways.1,2 This de-
centralization of HCV care has been catalysed by the availability, and 
increased affordability, of direct-acting antiviral (DAA) medications. 
These simple, effective and well-tolerated drugs no longer pose the 
extensive risk of harms associated with previous incarnations of HCV 
treatment.3 As such, they present an opportunity to deliver an effi-
cacious cost-effective HCV cure, in diverse non-specialist settings.4–6
In Scotland, injecting drug use continues to be the most im-
portant risk factor for HCV infection. Surveys of people who inject 
drugs (PWID) suggest over half are HCV antibody positive, with al-
most a third having evidence of current infection.7 The importance 
of decentralized HCV treatment in community locations is widely 
recognized as a key component to increasing treatment uptake, par-
ticularly among PWID.1,2 However, the role of non-specialist clini-
cians in prescribing that treatment has received scant attention to 
date. Community-based pathways in Scotland function as ‘outreach’ 
models of care, relying on specialist clinicians prescribing DAA treat-
ments in non-specialist settings.8 Such specialist clinicians comprise 
hospital-based doctors, nurses and pharmacists working in hepa-
tology or infectious diseases. This presents a potential barrier to 
maximizing treatment uptake, as engagement with specialist clini-
cians necessitates additional steps in patient pathways, presenting 
avoidable opportunities for disengagement. The capacity of these 
specialist teams may also be limited.9
Theoretically, general practitioners (GPs) have the authority to 
prescribe DAAs in Scotland. However, the ability to do so in prac-
tice is encumbered by fiscal considerations, as budgets for these 
drugs currently lie within specialist care, with area drug and ther-
apeutics committees and National Health Service (NHS) formulary 
committees imposing local prescribing restrictions to ‘specialist use’ 
alone.10,11 In addition, while GPs could prescribe DAAs, there is de-
bate around whether they should, located within narratives of clini-
cal expertise, responsibility and liability.12,13
In primary care settings around the globe, reported GP (or pri-
mary care provider) roles in HCV treatment vary considerably. For 
example, GPs have been the initiator of referrals into co-located 
services provided by specialist teams14; a shared care partner along-
side specialist clinicians in task-sharing collaborations15; and inde-
pendent HCV practitioners following comprehensive task-shifting 
from specialist care.16 Globally, therefore, GP involvement in HCV 
treatment is a broad church, and while diverse models have demon-
strated some success in other countries, the factors underpinning 
the success of such complex interventions are rarely established. 
As such, the optimal nature and extent of an expanded GP role are 
unclear.
This study aims to investigate context-specific barriers and en-
ablers to an expansion of the role of GPs in the treatment of HCV 
in Scotland. In doing so, we employ behaviour change theory as a 
conceptual framework, understanding that the implementation of 
new ways of working, or alteration of existing practice, necessitates 
changes in individual and collective behaviours.17
2  |  METHODS
2.1  |  Conceptual framework
The COM-B model developed by Michie and colleagues describes 
three interdependent components which interact to produce be-
haviour (B): capability (C), opportunity (O) and motivation (M).18 The 
model proposes that to enact a particular behaviour, an individual 
must be capable of doing so, be offered the opportunity to do so and 
be more motivated to do so than not at a particular time and place. 
The components influence one another, so that broadly speaking, 
an increase in capability or opportunity also increases motivation 
(Figure 1). The COM-B understanding of behaviour lies at the heart 
of the Behaviour Change Wheel (BCW), which offers a toolkit for 
designing behaviour change interventions19 (Figure 2). The centre of 
the BCW demonstrates how these three broad domains of capabil-
ity, opportunity and motivation include cognitive, affective, social 
and environmental influences. Capability incorporates psychologi-
cal (knowledge) and physical (skills) elements, opportunity mani-
fests in both social (societal influences) and physical (environmental 
resources) spheres, and motivation encompasses both automatic 
(emotion) and reflective (beliefs and intentions) constituents.18,19 As 
such, COM-B provides valuable insight, and a solid foundation for 
theoretically informed intervention development. We present our 
analysis through this lens.
2.2  |  Setting and sampling
The study was primarily located within the two NHS board areas 
in Scotland with the highest number of new HCV diagnoses 
in 2018.20 As the focus of the study was the provision of HCV 
F I G U R E  1  The COM-B system, a framework for understanding 
behaviour by Michie et al19
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treatment, target participants were care providers currently en-
gaged in that behaviour, and potential adopters of that behav-
iour.17 The decentralization of HCV treatment has implications for 
diverse stakeholders, and a purposive maximum variation sample 
was therefore applied to gain multiple perspectives from assorted 
participants. This sampling approach aims to ensure representa-
tiveness and diversity and emphasizes the significance of shared 
themes emerging from, and cutting across, participant heteroge-
neity.21 The sample comprised specialist HCV doctors, nurses and 
pharmacists working in hepatology and/or infectious diseases; 
GPs with an interest in HCV providing care for PWID; and staff 
from third-sector agencies supporting PWID onto and through 
HCV treatment. Third-sector agencies include non-governmental 
and not-for-profit organizations such as charities, advocacy and 
voluntary groups.
2.3  |  Participant recruitment
HCV specialists were recruited using the existing networks of 
DW and KD, who identified key clinicians in the two NHS boards. 
These clinicians were approached and invited to participate di-
rectly. GPs were recruited via two routes. First, the NHS Research 
Scotland Primary Care Network advertised the study in a monthly 
newsletter sent to all GPs within individual NHS boards, with GPs 
invited to contact the study team if interested in participating. GP 
recruitment by this method was expanded to other NHS boards 
following study inception. Second, the study team also used the 
Scottish Index of Multiple Deprivation (SIMD) to identify key GP 
practices within each NHS board. The SIMD identifies small area 
concentrations of significant deprivation by amalgamating data 
from seven domains: income, employment, education, health, 
housing, access to services and crime.22 Publically available email 
addresses were then used to contact GPs directly inviting them to 
participate. Third-sector organizations were identified by EH, ES 
and DW and were also approached directly, with the most appro-
priate potential participants within these organizations identified 
collaboratively.
2.4  |  Data generation
Data were generated with participants through semi-structured 
interviews held between October 2019 and March 2020. The 
majority of interviews were conducted in person by ES, although 
one interview employed teleconferencing software. Interviews 
lasted between 31 and 68 min, with a mean duration of 52 min. 
During interviews, topic guides were used to focus conversation, 
which consisted of open-ended questions relating to the domains 
of the COM-B model.18,19 Examples of questions included ‘what 
skills would a GP need to prescribe HCV treatment safely?’ (capabil-
ity/physical); ‘what systems would need to be in place to enable GPs 
to prescribe HCV treatment safely?’ (opportunity/physical); ‘if an ex-
pansion of GP-led HCV treatment was to go ahead, what would be 
the benefits and costs?’ (motivation/reflective). Topic guides were 
developed by DW, ES, LE and PF. While offering structure, inter-
views were conducted with a fluidity and flexibility that enabled 
the natural flow of conversation. Interviews with participants from 
different stakeholder groups were purposefully interspersed with 
one other, allowing initial insights gained to be explored from dif-
ferent perspectives. For example, potential barriers identified by 
one stakeholder could be followed up and contextualized from a 
different viewpoint fostering depth within the data. All interviews 
were recorded on an encrypted audio-recorder, and transcribed 
verbatim, after which identifiable participant information was re-
moved or obscured from the narrative.
F I G U R E  2  The behaviour change wheel by Michie et al19
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2.5  |  Analysis
Analysis was a two-step process. Initially, an established process 
of thematic analysis guided coding of the data.23 ES and DW read 
and reread the transcripts, which were then inductively coded using 
NVivo v.12 software to manage the data. While depicted as a linear 
process, interviewing and coding were conducted in parallel, with 
each task informing the other. This aided the identification of data 
sufficiency, as coding of the final transcripts aligned to codes already 
developed offering no fresh insight. During this early analysis, cod-
ing was regularly discussed and reviewed by DW and ES. Secondly, 
a deductive framework analysis was performed, where coded data 
were aligned with the three overarching components of the COM-B 
model (capability, opportunity and motivation). This stage of analysis 
was audited by PF, an HCPC Registered Health Psychologist, who 
interrogated the initial alignments, and provided a robust review of 
their coherence. Some coded data were realigned following this pro-
cess. Within each component, key subthemes were identified rel-
evant to the behaviour in question: the provision of HCV treatment 
by GPs.
3  |  RESULTS
Seventeen healthcare providers and five third-sector workers were 
recruited and interviewed. Two third-sector workers were inter-
viewed together at their request; all other interviews were con-
ducted individually. Participant characteristics are presented in 
Table 1.
3.1  |  Capability
The majority of participants considered contemporary DAA thera-
pies as requiring few skills and limited knowledge to prescribe. 
Despite this, the importance placed on training within the narratives 
was evident. Training was constructed as a necessity to increase 
confidence, familiarity and raise awareness among GPs, although 
the content and nature of such training were less well defined. While 
drug interactions and serology interpretation were flagged as impor-
tant by specialists, GP and third-sector workers discussed training in 
relation to risk awareness and HCV case finding, as well as enhanc-
ing GPs’ soft skills to help broach the topic with potentially at-risk 
individuals:
We might not always be aware of the risk. And if 
they've come in about something completely differ-
ent, I think there's potentially a bit of an issue with 
not necessarily routinely asking…it's difficult to bring 
it into conversation…. 
(GP)
Potential GP knowledge deficits were buffered by the concept of 
‘shared care’ between GPs and specialist services. Examples of shared 
care, such as the prescription of disease-modifying anti-rheumatic 
drugs and opioid substitution therapy, were presented as recognized 
collaborations between GPs and specialist teams, establishing ability 
by precedent. While the construction of shared care ranged from pa-
ternalistic supervision to more remote consultative guidance, it con-
sistently acted as an enabler of proficiency, providing a reservoir of 
expertise to draw upon when required:
As a GP I’m comfortable that I don't know everything. 
I’m quite happy that I can approach other people who 
have more day-to-day technical knowledge when I’m 
unsure about what's required. So I don't feel the need 
to know [everything], I just know that I can ask some-
body else. 
(GP)
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All groups of participants expressed concerns over the need for 
venous blood draws during HCV testing and treatment. Participants 
positioned venepuncture on PWID living with HCV as a challenging 
and labour-intensive pursuit, founded in narratives of ‘difficult veins’ 
and often doubt in personal technical ability. However, venepuncture 
was rarely the routine domain of GPs, with the experience and exper-
tise of practice nurse and phlebotomist colleagues more commonly 
employed. While practical from a provider perspective, this collabo-
rative working often necessitated additional appointments, thereby 
generating further obstacles to the engagement of PWID in HCV care. 
Although positioned within the narratives as gold standard, some par-
ticipants questioned the need for venepuncture at all, suggesting es-
sential results indicating proof of active HCV infection could be better 
obtained by other methods:
Because you can do dry blood spot tests and you can 
get a PCR and antigen and if you just want to do the 
basics, that's fine. 
(HCV specialist nurse)
3.2  |  Opportunity
The assessment of liver fibrosis was positioned as a pre-treatment 
prerequisite by all groups of participants, with treatment initiation 
contingent on its completion. While serologic tests were vulnerable 
to the vagaries of venepuncture, the ability of GPs to perform tran-
sient elastography was also constrained, by the logistics and costs 
to GP practices of obtaining, maintaining and training on the equip-
ment. However, while the importance of fibrosis staging was unani-
mously acknowledged, a few participants questioned whether the 
treatment of HCV, and the assessment of fibrosis, need necessarily 
be so inexorably entwined:
I think what confuses people is that there is treat-
ment of the virus, and then there is assessment and 
follow-up of liver disease. At the moment we do a bit 
of both…and I think this is historical. If the aim is elim-
ination of hepatitis C then just give everybody [names 
drug] for twelve weeks and you will achieve it. 
(HCV specialist physician)
All participants theorized that the physical location of GPs, at the 
heart of their communities, made them a convenient port of call for 
people who found engaging with geographically distant specialist care 
services difficult. Some noted that the ‘general’ in general practitioner 
afforded a degree of anonymity, as reasons for attendance could be 
easily disguised. For many, the opportunity to combine HCV treatment 
with other services provided by some GPs, notably the provision of 
opioid substitution therapy, made them well placed to engage:
I think the huge benefit is that the GP’s very acces-
sible, people are often coming regularly for other 
reasons which is, you know, often prescriptions for 
their drug scripts…it's that regular contact that makes 
a GP a really ideal place, because people are coming 
in anyway. 
(GP)
In addition, GP participants emphasized how they developed ther-
apeutic relationships over time with those in their care, with episodic 
contact slowly building trust and familiarity. Such utopian insights into 
the GP/PWID relationship were not universally shared, however, with 
some participants offering a note of caution:
I hear it time and again - the GP’s probably the last 
person they want to go and speak to. They've been 
judged in the past due to their behaviours, you know, 
addiction being one. Their self-esteem, their confi-
dence, self-worth have been trampled over time and 
time again. Would you go back? 
(Third-sector worker)
While the majority of participants positioned their narrative in re-
lation to people who currently use drugs, some also noted that GPs 
were well placed to engage with other at-risk groups. However, de-
spite their enabling geographic credentials, the constrained capacity 
of GPs was a powerful and recurrent theme. Time was a valuable and 
limited commodity, necessarily rationed to cope with competing de-
mands. Where would HCV treatment fit within already overflowing 
clinics? Reluctance to take on the ‘additional work’ of HCV treatment 
was rooted in an already onerous workload, and contextualized within 
a growing recruitment crisis in primary care:
It has to be seen within the context of where we are 
at the moment. There's a huge workforce crisis in gen-
eral practice so retention of GPs has become a huge 
problem. General practice is creaking at the seams. 
You've got GPs doing 13-hour days. I mean, that's why 
they're leaving the profession in droves, that's why 
you can't recruit GPs. 
(GP)
Movement of financial resource from specialist to primary care was 
a commonly cited solution to issues of capacity, theoretically releasing 
GP time to offer longer and dedicated HCV appointments. However, 
such a compartmentalized HCV service was already established in 
many GP practices, run successfully by HCV nurses providing outreach 
from their hospital base. The benefit of GPs providing HCV treatment 
was therefore located in their ability to do so on an ad hoc basis within 
the confines of routine clinics. Such an undertaking would require a 
treatment pathway of utmost simplicity:
I almost think primary care could sit on its own and 
manage hep C treatment…it would be like going to 
your GP with a sore throat or something like that, 
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you've got hepatitis C, quick look on the thing, I’ll get 
your treatment, there you go, come back and see me 
in eight weeks once it's finished. 
(HCV specialist physician)
While idyllic, such simplistic notions were blighted with concerns 
over how GP prescribed HCV treatment could be dispensed, paid for 
and monitored. Current practice necessitated DAA prescriptions were 
initiated within specialist care, often by a practitioner who had never 
seen or engaged with the prescription's intended recipient. Specialist 
participants positioned this remote prescribing practice as a result 
of complex budgetary, governance and logistical requirements, all 
of which introduced inherent lag in the system; a prescription could 
not be written and filled on the same day. A key overseer was also 
required, usually the specialist HCV pharmacist, to expedite the pro-
cess, liaise with community pharmacies, and collect data on treatment 
numbers. Such ‘behind the scenes’ work was positioned as an essential 
part of ensuring the viability of any GP treatment model.
3.3  |  Motivation
The simplicity of contemporary HCV treatment was extolled by 
most participants as the greatest enabler of GP provision. The drugs 
were understood as safe and straightforward, with little need for 
monitoring or medical input. To the majority, HCV treatment was 
just another tablet:
I explained to my colleagues, look, it's a tablet for 
eight weeks and there are no side effects; you just 
prescribe it. There's no reason you can't just look it up 
in the BNF [British National Formulary] the way we 
do for anything else and just prescribe it. 
(GP)
That said, the long history of HCV treatment as the domain of spe-
cialist care, constructed a belief in some third-sector and GP partici-
pants that it remained a ‘specialist disease’. For these individuals, HCV 
treatment was a complicated pursuit requiring specific expertise, and 
an unfamiliar extension of ‘generalist’ work. As such, faith in ability and 
intention to treat were reduced:
I don't see it as something that every GP would just 
feel they could do like they write prescriptions for an 
antibiotic for a urinary tract infection, because it's 
clearly more specialist than that. It's not simple. 
(GP)
Incentivization of GPs with payment was a frequently mentioned 
motivator to HCV treatment provision. However, the delivery of holis-
tic, person-centred care was also a key enabler within the narratives. 
All groups of participants emphasized GPs’ focus on patient priorities, 
their familiarity with the populations they serve, and their expertise at 
building relational capital to address broader concerns over time. HCV 
was ‘part of the job’, and should not be treated in isolation:
…if you start segregating parts of the job off, it isn't 
general practice to my mind anymore. If you don't do 
the complete package, then you're definitely discrim-
inating against some of your patients…. 
(GP)
However, HCV treatment was positioned as more complex than 
simply removing the virus. Treatment of physical disease was often 
couched as a secondary outcome, with the opportunity to address 
other physical, mental and social comorbidities a common motivating 
factor. Why treat the virus without tackling the causes? This ratio-
nale was not only rooted in a desire to improve quality of life, but also 
founded in concerns of HCV reinfection. Participants eulogized the 
role HCV nurses currently played in holistic assessment, and expressed 
concern that this facet of HCV treatment was at risk:
…the success of hepatitis C treatment has been the 
support, or additional psycho-social care, and links 
that the specialist nurses have provided…and some-
times I think we're in danger of throwing the baby out 
with the bathwater, because we're so focused on, oh, 
it's just so easy, and actually are the patients losing 
the holistic care that specialist nurses bring? 
(HCV pharmacist)
That said, the rarity of treating physical disease rather than manag-
ing chronic illness was repeatedly emphasized as a powerful motivator 
by GP participants. The professional satisfaction and novelty of curing 
an illness were recurrently described:
…as a GP you hardly ever get to cure anything, you 
know? I mean, we don't get to do that with asthma or 
mental health problems or anything. So that is really 
rewarding, to say I’ve cured you. It's kind of why, in 
your fantasies, you went to medical school in the first 
place. 
(GP)
Such patient-centred motivators formed a robust theme within the 
data from all participants. While public health targets were alluded to, 
these remained the concern of HCV specialists alone, notably HCV 
specialist physicians.
4  |  DISCUSSION
The application of simple behaviour change theory (COM-B) pro-
vides a useful lens through which provider- and systemic-level bar-
riers and enablers to GP provision of HCV treatment in Scotland 
can be explored. Figure 3 emphasizes that identified barriers to 
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treatment primarily related to resources and the environmental con-
text, predominantly located within the opportunity domain of COM-
B. However, motivation also showed importance when identified 
enablers of the behaviour were considered. While provision of HCV 
treatment by GPs is the focus of this study, that behaviour must be 
considered within the HCV care cascade. Implicit in our findings was 
an understanding that HCV treatment is inextricably tied to HCV 
testing, and Figure 3 also details barriers and enablers to this behav-
iour identified in a recent review for context.24 When coupling the 
COM-B model with the wider BCW19 (Figure 2), our analysis, and the 
review findings,24 suggests interventions to expand the role of GPs 
in HCV testing should draw primarily upon functions of ‘education’ 
and ‘training’. Future intervention functions in relation to HCV treat-
ment should address key areas such as ‘environmental restructuring’, 
‘modelling’ and ‘enablement’.
Expanding the role of GPs in relation to HCV treatment aims to 
capitalize on interventions designed to systematically identify and 
test individuals in primary care, closing gaps in the care cascade. For 
example, the HepCATT study in England demonstrated the effec-
tiveness of a low-cost intervention (which included key education/
training elements) to increase HCV diagnoses in general prac-
tice.25,26 However, the model relied on subsequent engagement with 
specialist services to translate this into improved treatment num-
bers. This cavity in the care cascade has also been demonstrated in 
other studies,27,28 and an expansion of GP practice to initiate HCV 
therapy could help facilitate its closure.29
While our study was located within Scotland, the results align 
with findings from across the globe. Similar barriers and facilitators 
to GP prescribing have been reported from other countries,30–34 
emphasizing obstacles to sustainable models of GP-led treatment 
endure in the face of simple, effective DAA regimens. However, this 
study also contributes new knowledge to the field by disentangling 
commonplace understandings of ‘HCV treatment’, and illuminating 
the complex and multifaceted nature of the task. Our participants 
constructed ‘HCV treatment’ as much more than virus removal, re-
vealing a perception that was triumvirate in nature. This triumvirate 
incorporated, sequentially; the assessment of liver fibrosis, the pro-
vision of holistic support and the treatment of disease. This trinity 
arose from necessity in the interferon era and continued through 
the evolution of DAA therapy,35 but imposes a fundamental barrier 
to contemporary GP-led treatment: there are three tasks to accom-
plish, rather than one.
With this in mind, the constraints on GP time and capacity de-
mand a pragmatic re-examination of this ‘HCV treatment triumvi-
rate’ in order to address obstinate barriers to change, rather than 
attempting to replicate existing provision. For example, the assess-
ment of liver fibrosis for people living with HCV forms an integral and 
vital component of their care, but can present a significant barrier to 
treatment initiation in primary care settings.31,33,34 Historically, the 
importance of fibrosis staging informed not only ongoing follow-up 
and monitoring for cirrhosis and hepatocellular carcinoma, but was 
also predictive of treatment success, designating it a pre-treatment 
F I G U R E  3  Provider-related barriers and enablers of HCV treatment provision by GPs stratified by COM-B, contextualized by a scoping 
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necessity.36 However, the availability of pangenotypic DAA reg-
imens, efficacious and safe in both the presence and absence of 
compensated cirrhosis,37 questions not the absolute importance of 
fibrosis assessment, but offers flexibility in the timing of its provision. 
Contemporary DAA treatment allows the dogmatic pre-treatment 
assessment of liver fibrosis to be rethought, and a simpler pathway 
to treatment initiation forged. GP provision of HCV treatment may 
benefit from a ‘treat and refer’ model of care, rather than the ‘refer 
and treat’ status quo of many community-based pathways.8
A sole focus on the medical aspects of HCV therapy ignores the 
importance of holistic care, which resonated through our findings. 
Although DAAs exhibit few side effects,37 and appear forgiving in 
terms of adherence,38 care providers recognized the significance of 
ongoing person-centred social support as a vital component of HCV 
treatment. This is unsurprising, as the burden of HCV infection in 
Scotland is disproportionately felt within disenfranchised, vulnerable 
and underserved communities, for who, in the right environment, the 
treatment of HCV may have transformative potential.39 However, so-
cial support should not be positioned as providing ‘additional benefit’ 
during the treatment of physical disease, but as an integral part of the 
process. A recent systematic review emphasized how peer support 
and connection to relevant services bolsters community-based HCV 
treatment initiation and completion.40 Indeed, factors such as hous-
ing, finances, legal difficulties and drug use have repeatedly been cited 
as barriers for people living with HCV to engaging with care.28,41–43 
As part of the HCV treatment triumvirate, the provision of holistic 
support is therefore indispensable, and integrating that support into 
increasingly simplified and shortened treatment pathways will be an 
essential challenge moving forward. The lives of people living with 
HCV remain complex in the era of simple HCV therapies.
Our study has a number of strengths and limitations. First, our sam-
ple provided a multidisciplinary, inter-speciality insight from healthcare 
providers into barriers and enablers of HCV treatment provision by 
GPs. To focus the study, we purposefully recruited individuals involved 
in the provision of healthcare; however, some third-sector workers 
also had lived experience of HCV and its treatment which informed 
their narrative. Second, GP participants were self-selected, recruited 
in response to an advert or direct approach. As such, they represent a 
particularly motivated group with a specific interest in the topic, and 
may not be representative of Scottish GPs as a whole. The majority of 
GP participants also had some experience of involvement in shared 
care for HCV through local arrangements with HCV specialists. GPs 
providing care for PWID but who had no experience in HCV care were 
therefore an under-represented group. Third, the majority of partici-
pants were from two large urban centres in Scotland, and the barriers 
and enablers identified may not fully embody the experience of health-
care provision in more rural localities.
5  |  CONCLUSION
The modern era of DAA therapy provides opportunity to decentralize 
HCV care, with GP-led treatment a crucial strand in the battalion of 
community-based pathways aimed at viral elimination. However, to fa-
cilitate the provision of HCV treatment by GPs, simplicity and pragma-
tism are essential to overcome significant limitations on GP capacity. 
While not advocating the sacrifice of either liver fibrosis evaluation or 
the provision of support from the HCV treatment triumvirate, contem-
porary therapy offers the possibility of reimagining how these pieces 
fit together, challenging the ‘refer and treat’ status quo. To enable a 
streamlined, sustainable and effective pathway to HCV treatment pro-
vision by GPs, the treatment model must be reimagined, rather than 
simply relocated from specialist care. Within this paper, we have used 
COM-B and alluded to the Behaviour Change Wheel to sketch the 
likely direction of future interventions to implement GP provision of 
HCV treatment. Within subsequent work, we will examine these issues 
in more detail and articulate specific ways forward.
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